Comparative Pharmacology
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus ZEBETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus ZEBETA.
ACEBUTOLOL HYDROCHLORIDE vs ZEBETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker) with intrinsic sympathomimetic activity (ISA). Competitively blocks catecholamine binding at cardiac beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure. ISA provides mild beta-receptor stimulation, decreasing the extent of resting bradycardia and lipid changes.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker). Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Dose: 200-800 mg/day orally in 1-2 divided doses. Initially 200 mg twice daily; may increase to 400 mg twice daily as needed.
Initial dose 5 mg orally twice daily; may increase to 10 mg twice daily after 2 weeks; maximum 20 mg twice daily.
None Documented
None Documented
3-4 hours for acebutolol; 8-13 hours for diacetolol (active metabolite); clinically significant in renal impairment
Terminal elimination half-life is 12–15 hours in patients with normal renal function, allowing once-daily dosing.
Renal: 30-40% as unchanged drug and 50-60% as diacetolol; fecal: ~10%
Approximately 50% of an oral dose is excreted unchanged in urine; the remainder is hepatically metabolized with biliary excretion of metabolites contributing to fecal elimination.
Category C
Category C
Beta Blocker
Beta Blocker